Recent research analyzed factors influencing the selection of the first-line biologic medications and the real-life factors that lead to switching from those medications to other biologics in treating rheumatoid arthritis (RA). The study compared the use of abatacept and tocilizumab with a tumor necrosis factor alpha inhibitor (TNFi).1,2 Participants were enrolled in the Lombardy Rheumatology…
WASHINGTON, D.C.—Experts speaking at the 2016 ACR/ARHP Annual Meeting session, Update on Small-Vessel Vasculitis, offered insight into the latest approaches to the diagnosis and treatment of diseases involving the inflammation of blood vessels. “Vasculitis is an immune-mediated process. White blood cells invade the vessel wall, causing inflammation throughout the vessel wall,” said Jason M. Springer,…
Throughout their training and practice, physicians become adept at pattern recognition as a means to efficiently connect and synthesize seemingly disparate laboratory, physical exam, and radiologic and historical findings into a coherent theory for what likely ails the patient sitting in front of them. This inductive method of reasoning is necessary because, based on these…
“You can’t win last night’s game again.” —George Karl, professional basketball player and coach Amid the angst and upheaval from our recent elections and associated uncertainty for future healthcare policies, one thing remains clear: We must increase our engagement with our elected officials to educate them on the needs of our profession and our patients….
NEW YORK (Reuters Health)—Inpatient rehabilitation did not lead to better mobility following total knee replacement compared with a home-based program in a randomized controlled trial (RCT) conducted in Australia. The findings do not support inpatient rehabilitation for adults undergoing uncomplicated total knee arthroplasty, conclude the authors in JAMA on March 14.1 “Normally, one study is…
The FDA is considering a supplemental biologics license application for tocilizumab to treat giant cell arteritis…
Guselkumab Improves Active Psoriatic Arthritis New research has revealed that patients with active psoriatic arthritis (PsA) and ≥3% body area of plaque psoriasis benefit from treatment with a human monoclonal antibody known as guselkumab (GUS). GUS is specific for the p19 subunit of interleukin 23 (IL-23). Patients in the Phase 2 clinical trial experienced significant…
NEW YORK (Reuters Health)—Members of the military and firefighters are at increased risk of osteoarthritis (OA), a new systematic review shows. “Osteoarthritis is more common in people who are tactical athletes, people who are firefighters and military service members, than it is in the general population,” Dr. Kenneth Cameron of Keller Army Hospital in West…
NEW YORK (Reuters Health)—Early or late mobilization after rotator cuff surgery appears to yield similar outcomes, according to a new meta-analysis. Dr. Bruno Fles Mazuquin from the University of Central Lancashire in the U.K., and colleagues conducted an overview of systematic reviews comparing the effectiveness of early and conservative rehabilitation after rotator cuff repair. The…
The ACR has released a statement, responding positively to the release of the latest U.S. Food and Drug Administration (FDA) draft guidance on biosimilar drug development. Also, BI 695501, a biosimilar to Humira (adalimumab) made by Boehringer Ingelheim, has been accepted for regulatory review in both the U.S. and Europe. ACR Responds to FDA Biosimilar…